Erasca, INC.(ERAS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ERAS Erasca, INC.

已收盘 09-08 16:00:00 EDT

16.28

+0.09

+0.56%

盘后15.98

-0.30-1.81%

19:37 EDT

最高16.65	最低15.68	成交量426.47万
今开15.88	昨收16.19	日振幅5.99%
总市值56.94亿	流通市值47.40亿	总股本3.50亿
成交额6,975万	换手率1.46%	流通股本2.91亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ERAS","market":"US","secType":"STK","nameCN":"Erasca, INC.","latestPrice":16.28,"timestamp":1788897600000,"preClose":16.19,"halted":0,"volume":4264686,"hourTrading":{"tag":"盘后","latestPrice":15.9848,"preClose":16.28,"latestTime":"19:37 EDT","volume":12860,"amount":209336.4696,"timestamp":1788910676064,"change":-0.2952,"changeRate":-0.018133,"amplitude":0.019361},"delay":0,"changeRate":0.005558987029030256,"floatShares":291145893,"shares":349762000,"eps":-0.970994,"marketStatus":"已收盘","change":0.09,"latestTime":"09-08 16:00:00 EDT","open":15.88,"high":16.65,"low":15.68,"amount":69751378.930392,"amplitude":0.059914,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.970994,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1788940800000},"marketStatusCode":5,"adr":0,"listingDate":1626408000000,"exchange":"NASDAQ","adjPreClose":16.19,"preHourTrading":{"tag":"盘前","latestPrice":15.8,"preClose":16.19,"latestTime":"09:27 EDT","volume":4327,"amount":70047.661135,"timestamp":1788874070067,"change":-0.39,"changeRate":-0.024089,"amplitude":0.088975},"postHourTrading":{"tag":"盘后","latestPrice":15.9848,"preClose":16.28,"latestTime":"19:37 EDT","volume":12860,"amount":209336.4696,"timestamp":1788910676064,"change":-0.2952,"changeRate":-0.018133,"amplitude":0.019361},"volumeRatio":0.95139,"impliedVol":0.9987,"impliedVolPercentile":0.4462},"requestUrl":"/m/hq/s/ERAS","defaultTab":"news","newsList":[{"id":"1185916118","title":"Erasca计划针对ERAS-0015在胰腺癌和肺癌领域开展三项可能支持注册的关键性试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1185916118","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185916118?lang=zh_cn&edition=full","pubTime":"2026-08-24 20:03","pubTimestamp":1787573033,"startTime":"0","endTime":"0","summary":"Erasca公司宣布，其计划针对候选药物ERAS-0015启动三项可能支持注册的关键性临床试验，适应症覆盖胰腺癌和肺癌领域。此举标志着该公司在肿瘤治疗管线推进上迈出重要一步，显示出其对这一候选药物的战略布局和临床开发决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ERAS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186350763","title":"Erasca获FDA快速通道认定：泛Ras分子胶Eras-0015进军转移性胰腺癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1186350763","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186350763?lang=zh_cn&edition=full","pubTime":"2026-08-24 20:01","pubTimestamp":1787572917,"startTime":"0","endTime":"0","summary":"生物医药领域再传重磅消息——Erasca公司宣布，其自主研发的泛Ras分子胶候选药物Eras-0015，已成功获得美国食品药品监督管理局授予的快速通道认定。这一认定针对的适应症，正是临床需求极为迫切的转移性胰腺导管腺癌。获得这一资格，不仅肯定了Eras-0015在临床前及早期临床研究中展现出的潜力，也为其后续的注册路径铺平了道路。胰腺癌治疗格局正面临深刻重塑。而Eras-0015，正是这一探索浪潮中的最新弄潮儿。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ERAS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145327228","title":"新闻稿：Erasca 依据纳斯达克上市规则第5635(c)(4)条授予激励性股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1145327228","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145327228?lang=zh_cn&edition=full","pubTime":"2026-08-11 04:03","pubTimestamp":1786392238,"startTime":"0","endTime":"0","summary":"该股票期权于2026年8月10日授予，行权价格定为授予当日Erasca普通股在纳斯达克全球精选市场上的收盘价。根据纳斯达克上市规则第5635条，此项激励计划专门用于向此前并非Erasca员工、或经历一段真正的非雇佣期后，作为其入职Erasca的重要诱因而授予股权奖励的个人。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QQQM",".IXIC","QDTE","SQQQ","TQQY","NDX","QQQA","ONEQ","BK4139","BK4539","MNQmain","PSQ","QQQE","TQQQ","FTEC","QID","QQQY","GPIQ","ERAS","TECS","QYLG","QQQ","QLD","IYW","NVIW.SI","JEPQ","QQQJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123280089","title":"异动解读｜Erasca盘中下跌5.27%，6.325亿美元扩大股票发行完成引发稀释担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1123280089","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123280089?lang=zh_cn&edition=full","pubTime":"2026-07-16 23:57","pubTimestamp":1784217434,"startTime":"0","endTime":"0","summary":"7月16日，Erasca盘中下跌5.27%，报20.14美元/股，成交额3885.03万美元。该发行规模较最初计划的5亿美元显著扩大，且发行价格低于当前交易价，市场对大额股权稀释的担忧成为股价承压的主要因素。Erasca是一家临床阶段精准肿瘤学公司，专注于为RAS/MAPK通路驱动的癌症患者发现、开发和商业化疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERAS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175483649","title":"异动解读｜Erasca盘中上涨5.41%，积极临床数据及注册推进计划提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1175483649","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175483649?lang=zh_cn&edition=full","pubTime":"2026-07-15 22:40","pubTimestamp":1784126419,"startTime":"0","endTime":"0","summary":"7月15日，Erasca盘中上涨5.41%，报20.58美元/股，成交额4289.97万美元。尽管公司同日宣布拟公开发行5亿美元普通股，盘后一度因稀释担忧下跌3.5%，但积极的临床进展及明确的注册路径显著提振了市场对公司长期价值的信心，推动股价在次日交易时段走强。Erasca是一家临床阶段精准肿瘤学公司，专注于为RAS/MAPK通路驱动的癌症患者发现、开发和商业化疗法。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERAS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124567538","title":"Erasca盘后股价下挫3.5%，拟公开发行5亿美元普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1124567538","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124567538?lang=zh_cn&edition=full","pubTime":"2026-07-14 04:40","pubTimestamp":1783975244,"startTime":"0","endTime":"0","summary":"生物科技公司Erasca股价在盘后交易时段下跌3.5%。公司于同日宣布，计划通过公开发行筹集高达5亿美元的资金，发行标的为普通股。此项融资提案旨在为公司运营及管线开发提供资金支持。市场对股权稀释的担忧，或是导致股价在消息公布后应声走低的主要原因。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","ERAS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171279469","title":"Erasca计划在2027年上半年启动支持注册的肺癌试验；胰腺癌III期试验定于2027年","url":"https://stock-news.laohu8.com/highlight/detail?id=1171279469","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171279469?lang=zh_cn&edition=full","pubTime":"2026-07-14 04:05","pubTimestamp":1783973115,"startTime":"0","endTime":"0","summary":"Erasca公司宣布了其临床开发管线的重要规划。该公司计划在2027年上半年启动一项旨在支持新药注册的肺癌临床试验。此外，针对胰腺癌的III期关键性试验也已提上日程，预计将在2027年展开。\n这两项试验的推进标志着Erasca在肿瘤治疗领域的研究进入了新的阶段。肺癌和胰腺癌均是全球范围内发病率和死亡率较高的癌症类型，存在巨大的未满足医疗需求。公司此举旨在通过临床研究，为患者带来新的治疗希望。\n具体试验设计、患者招募标准以及详细的实施时间表，预计将在后续适时公布。行业观察者正密切关注Erasca的研发进展，这些试验结果可能对未来癌症治疗格局产生影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ERAS","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140568937","title":"Erasca公布潜在最优级泛Ras分子胶Eras-0015在Kras突变实体瘤中的更新初步一期数据及注册推进计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1140568937","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140568937?lang=zh_cn&edition=full","pubTime":"2026-07-14 04:02","pubTimestamp":1783972937,"startTime":"0","endTime":"0","summary":"Erasca公司今日宣布，针对其潜在最优级的泛Ras分子胶药物Eras-0015，在治疗Kras突变实体瘤方面，已公布了更新的初步一期临床试验数据，并同步披露了旨在推动该药物实现注册上市的关键计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ERAS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155239287","title":"异动解读｜Erasca盘中上涨9.64%，报11.315美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1155239287","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155239287?lang=zh_cn&edition=full","pubTime":"2026-05-21 00:13","pubTimestamp":1779293612,"startTime":"0","endTime":"0","summary":"5月21日，Erasca盘中上涨9.64%，报11.315美元/股，成交额3731.19万美元。Erasca所在的生物科技行业中，个股中，HCW Biologics涨96.24%，Immunovant涨33.66%，Roivant Sciences涨14.34%，安进跌0.01%，艾伯维公司跌0.61%。Erasca是一家临床阶段的精准肿瘤学公司，专注于发现、开发和商业化RAS/MAPK通路驱动癌症患者的疗法，旨在创造新的疗法和联合方案以全面关闭RAS/MAPK通路治疗癌症。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERAS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148385071","title":"Erasca宣布与默克达成临床试验合作与供应协议，共同评估Eras-0015联合Keytruda®（帕博利珠单抗）的疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1148385071","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148385071?lang=zh_cn&edition=full","pubTime":"2026-05-11 19:01","pubTimestamp":1778497277,"startTime":"0","endTime":"0","summary":"Erasca公司已正式宣布，其与默克公司达成了一项临床试验合作与供应协议。根据该协议，双方将共同开展临床研究，以评估Erasca旗下在研药物Eras-0015与默克的明星产品Keytruda®（通用名：帕博利珠单抗）联合使用的潜力。此项合作旨在探索该联合疗法在相关适应症中的安全性与有效性，标志着两家公司在肿瘤治疗领域研发合作的重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ERAS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157186995","title":"异动解读 | 临床受试者死亡及专利纠纷引发担忧，Erasca股价盘中大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157186995","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157186995?lang=zh_cn&edition=full","pubTime":"2026-04-29 21:33","pubTimestamp":1777469586,"startTime":"0","endTime":"0","summary":"生物制药公司Erasca, INC.(ERAS)今日盘中股价大跌5.05%，引起了市场关注。消息面上，该公司近期遭遇双重挫折。首先，其抗癌药物的临床试验中出现一名患者死亡案例，该患者曾出现与治疗相关的严重副作用，这引发了市场对其疗法安全性的严重质疑。其次，该公司收到了竞争对手Revolution Medicines发出的停止侵权函，指控其癌症疗法侵犯了对方专利，这为公司带来了潜在的法律风险和市场不确定性。这些负面事件叠加，打击了投资者信心。分析人士指出，临床安全性问题和专利纠纷是生物科技公司股价波动的关键风险因素，预计相关不确定性将持续对Erasca的股价构成压力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ERAS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631399554","title":"临床受试者死亡引发安全疑虑：癌症药研发商Erasca(ERAS.US)股价遭“腰斩”，单日暴跌48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631399554","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2631399554?lang=zh_cn&edition=full","pubTime":"2026-04-29 10:50","pubTimestamp":1777431021,"startTime":"0","endTime":"0","summary":"智通财经APP注意到，Erasca股价于周二暴跌 48%，此前这家抗癌药物研发商表示，一名患者在退出临床试验后死亡，该患者曾出现与治疗相关的严重副作用。Erasca 的代表未立即回应置评请求。这一消息是该药物研发商在连续两天内遭遇的第二次挫折。周一，Erasca 收到了竞争对手 Revolution Medicines Inc.  发出的停止侵权函，指控 Erasca 的癌症疗法与Revolution Medicines 某项专利所主张的某些成分“实质等同”。Erasca 股价周一已下跌 11%。在 Erasca 遭遇挫折后，Revolution Medicines股价周二上涨了 10%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK4539","ERAS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146280315","title":"Erasca股价盘前暴跌36.6% 公司公布实验性癌症疗法早期试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1146280315","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146280315?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:58","pubTimestamp":1777366696,"startTime":"0","endTime":"0","summary":"生物制药公司Erasca, Inc. (ERAS) 股价在盘前交易中重挫36.6%，此前该公司公布了其实验性癌症疗法的早期临床试验数据。此次股价大幅波动直接反映了市场对该初步研究结果的评估。\n该公司专注于开发针对难治性癌症的创新疗法，本次公布的早期阶段试验结果备受投资者关注。股价的剧烈反应通常预示着市场对临床数据前景的重新定价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ERAS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154548519","title":"异动解读 | Erasca盘前暴跌34.78%，遭同行知识产权诉讼指控核心药物研发面临叫停风险","url":"https://stock-news.laohu8.com/highlight/detail?id=1154548519","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154548519?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:10","pubTimestamp":1777363805,"startTime":"0","endTime":"0","summary":"生物科技公司Erasca, INC.  今日盘前股价大跌34.78%，引发了市场的广泛关注。首先，同行公司Revolution Medicines通过SEC文件指控Erasca涉嫌不当使用与其核心药物ERAS-0015相关的商业秘密，并要求其停止该药物在美国境内的所有研发活动。这一突如其来的法律纠纷为Erasca的核心管线前景蒙上了巨大的不确定性阴影。盘前的暴跌反映出市场正在对潜在的诉讼风险及研发受阻的可能性进行紧急重估。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ERAS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110827257","title":"异动解读 | Erasca夜盘大跌30.08%，知识产权诉讼风险与关键临床数据窗口迫近引发抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=1110827257","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110827257?lang=zh_cn&edition=full","pubTime":"2026-04-28 15:35","pubTimestamp":1777361756,"startTime":"0","endTime":"0","summary":"生物科技公司Erasca, INC.  在夜盘时段股价大跌30.08%，市场关注度显著上升。首先，同行公司Revolution Medicines通过SEC文件指控Erasca涉嫌不当使用与其核心药物ERAS-0015相关的商业秘密，并要求其停止该药物在美国境内的所有研发活动。这一突如其来的法律纠纷为Erasca的核心管线前景蒙上了巨大的不确定性阴影。夜盘的暴跌反映出市场正在对潜在的诉讼风险及研发受阻的可能性进行紧急重估。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ERAS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186741008","title":"美股夜盘 | 新美亚电子绩后涨近15%，Rambus大跌12%；Erasca遭窃密指控暴跌34%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186741008","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186741008?lang=zh_cn&edition=full","pubTime":"2026-04-28 08:35","pubTimestamp":1777336525,"startTime":"0","endTime":"0","summary":"4月28日，美股夜盘时段，$新美亚电子$涨近15%，上财季营收40.1亿美元超预期；Erasca暴跌34%，RVMD涨近8%。Erasca遭$Revolution Medicines$指控窃取商业秘密；Bed Bath & Beyond暴涨25%！一季度销售额超市场预期；$LendingClub$涨超10%，第一季度业绩超出预期；$纽柯钢铁$涨超3%，Q1营收超出市场预期；$Joby Aviation$续涨超4%，在纽约完成了首次eVTOL空中出租车演示飞行；$Rambus$下跌12%。第一季度经调整营业利润率为42%，低于去年同期的46%；$天弘科技$绩后跌近9%，4月以来已累涨近50%。","market":"us","thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SANM","IE00B19Z6F94.USD","BK4585","BK4141","BK4539","IE0034390439.USD","BK4139","RMBS","BK4145","ERAS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178546676","title":"Erasca公司遭Revolution Medicines指控涉嫌窃取Eras-0015相关商业秘密","url":"https://stock-news.laohu8.com/highlight/detail?id=1178546676","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178546676?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:44","pubTimestamp":1777293852,"startTime":"0","endTime":"0","summary":"生物制药企业Erasca, Inc.近日面临重大法律挑战。同行公司Revolution Medicines正式向美国证券交易委员会提交文件，指控其涉嫌不当使用与核心研发项目Eras-0015相关的商业秘密。这一指控直指Erasca公司的知识产权合规体系。目前双方尚未就具体争议细节发表进一步声明。但该事件已引发投资界对生物科技领域知识产权保护现状的高度关注。随着监管机构介入调查，事件进展将对Erasca公司的研发前景与市场估值产生深远影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ERAS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198479523","title":"革命医药公司要求Erasca停止Eras-0015在美国活动及对比声明——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1198479523","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198479523?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:39","pubTimestamp":1777293562,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）最新公开文件显示，生物制药公司革命医药（Revolution Medicines）已正式要求Erasca公司立即停止其抗癌药物Eras-0015在美国境内的所有研发及商业推广活动。\n文件进一步透露，革命医药还要求Erasca终止所有涉及Eras-0015与其他药物的对比性声明。这一法律要求凸显了两家公司在肿瘤治疗领域知识产权方面的潜在冲突。\n目前Erasca公司尚未就此事作出公开回应。市场密切关注这一纠纷可能对双方药物研发进度及资本市场表现产生的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","ERAS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149564829","title":"Erasca公司明确Eras-0015一期临床数据公布时限：不晚于2026年5月中旬","url":"https://stock-news.laohu8.com/highlight/detail?id=1149564829","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149564829?lang=zh_cn&edition=full","pubTime":"2026-04-21 21:13","pubTimestamp":1776777210,"startTime":"0","endTime":"0","summary":"生物制药公司Erasca, Inc. (纳斯达克代码: ERAS) 通过最新提交的SEC文件披露，其核心候选药物Eras-0015的一期临床试验数据读取时间范围已进一步收窄。公司明确表示，这项备受业界关注的数据预计将在2026年5月中旬之前正式公布。\n此次时间节点的明确，为市场观察者提供了更清晰的时间框架，以评估该药物在早期临床研究中的潜力与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ERAS","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518020919","title":"Erasca, Inc.盘中异动 股价大跌5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518020919","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518020919?lang=zh_cn&edition=full","pubTime":"2025-03-11 02:08","pubTimestamp":1741630106,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日02时08分，Erasca, Inc.股票出现波动，股价快速下跌5.23%。截至发稿，该股报1.45美元/股，成交量100.523万股，换手率0.36%，振幅6.86%。Erasca, Inc.股票所在的生物技术行业中，整体涨幅为0.70%。Erasca, Inc.公司简介：Erasca Inc 是一家临床阶段的精准肿瘤学公司，专注于为 RAS / MAPK 通路驱动的癌症患者发现、开发和商业化疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311020826a26a8b47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311020826a26a8b47&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","ERAS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.erasca.com","stockEarnings":[{"period":"1week","weight":-0.1021},{"period":"1month","weight":-0.1305},{"period":"3month","weight":0.3525},{"period":"6month","weight":0.0465},{"period":"1year","weight":9.9392},{"period":"ytd","weight":3.3522}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0443},{"period":"6month","weight":0.1455},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1294}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Erasca, Inc.于2018年7月2日在特拉华州注册成立。该公司是一家临床阶段的精准肿瘤学公司，专注于发现、开发和商业化RAS/MAPK通路驱动癌症患者的疗法。该公司由精准肿瘤学和RAS靶向领域的领先先驱共同创立，旨在创造新的疗法和联合方案，旨在全面关闭RAS/MAPK通路以治疗癌症。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":0.210192},{"month":2,"riseRate":0.6,"avgChangeRate":0.079229},{"month":3,"riseRate":0.2,"avgChangeRate":-0.084063},{"month":4,"riseRate":0.2,"avgChangeRate":-0.107381},{"month":5,"riseRate":0.4,"avgChangeRate":0.028932},{"month":6,"riseRate":0.6,"avgChangeRate":0.063313},{"month":7,"riseRate":0.6,"avgChangeRate":0.149968},{"month":8,"riseRate":0.5,"avgChangeRate":0.054674},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.041415},{"month":10,"riseRate":0.6,"avgChangeRate":0.042195},{"month":11,"riseRate":0.4,"avgChangeRate":-0.041882},{"month":12,"riseRate":0.6,"avgChangeRate":-0.005114}],"exchange":"NASDAQ","name":"Erasca, INC.","nameEN":"Erasca, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Erasca, INC.(ERAS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Erasca, INC.(ERAS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Erasca, INC.,ERAS,Erasca, INC.股票,Erasca, INC.股票老虎,Erasca, INC.股票老虎国际,Erasca, INC.行情,Erasca, INC.股票行情,Erasca, INC.股价,Erasca, INC.股市,Erasca, INC.股票价格,Erasca, INC.股票交易,Erasca, INC.股票购买,Erasca, INC.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Erasca, INC.(ERAS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Erasca, INC.(ERAS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}